jobs.jnj.com/en/jobs/
Skip to content
✕
Internet Explorer is no longer supported by this website.
For optimal browsing we recommend using
Chrome
,
Firefox
or
Safari
.
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Menu
Search
Toggle Menu
Change Country
Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
About J&J
Our Credo
Our Leadership Team
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health and Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Products
MedTech
Pharmaceutical Products
Suppliers
Responsible Supply Base
Supplier-Enabled Innovation
Supplier Resources
Careers
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Media Center
Investors
2023 Annual Meeting of Shareholders
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2021 Janssen Transparency Report
2021 Health for Humanity Report
ESG Investor Update
ESG Resources
Stock Information
Webcasts & Presentations
Investor Fact Sheet
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Sustainability
Close Countries Menu
Explore more Johnson & Johnson sites:
China
France
Germany
India
Japan
Russia
Switzerland
German
English
French
United Kingdom
United States
Close Search Menu
Search input
Share
COVID-19 Statements
MEDIA STATEMENT
May 05, 2022
Johnson & Johnson Updates U.S. COVID-19 Vaccine Fact Sheet
Media Statement
April 04, 2022
World Health Organization Updated Emergency Use Listing Recommends Johnson & Johnson COVID-19 Vaccine for Booster Use
MEDIA STATEMENT
December 16, 2021
Johnson & Johnson Statement on its COVID-19 Vaccine Following CDC ACIP Meeting
December 16, 2021
Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC
Media Statement
November 30, 2021
Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage
Media Statement
November 29, 2021
Johnson & Johnson to Evaluate Its COVID-19 Vaccine Against New Omicron COVID-19 Variant
Media Statement
November 22, 2021
Almost 100 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to Lower Income Countries Through COVAX
Media Statement
October 18, 2021
17 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to African Union Countries
MEDIA STATEMENT
August 18, 2021
Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine
Media Statement
July 28, 2021
Johnson & Johnson Statement on U.S. FDA Approval of Shelf Life Extension for Company’s COVID-19 Vaccine
Our Company
July 12, 2021
Johnson & Johnson Statement on COVID-19 Vaccine (7/12)
Our Company
June 11, 2021
Johnson & Johnson Statement on Supply of its Single-shot COVID-19 Vaccine
Our Company
April 23, 2021
Johnson & Johnson Statement on April 23 CDC Advisory Committee Meeting on Company COVID-19 Vaccine
Our Company
April 21, 2021
Johnson & Johnson Statement on FDA Observations at Emergent BioSolutions (Updated 4/30)
Our Company
April 14, 2021
Johnson & Johnson Statement on CDC Advisory Committee Meeting on Company COVID-19 Vaccine
Our Company
April 13, 2021
Johnson & Johnson Statement on COVID-19 Vaccine (Updated)
Our Company
April 03, 2021
Johnson & Johnson Statement on U.S. COVID-19 Vaccine Manufacturing (Updated)
Our Company
March 31, 2021
Johnson & Johnson Statement on U.S. COVID-19 Vaccine Manufacturing
Our Company
March 17, 2021
Statement on the Interim SAGE Recommendation Supporting the Use of the Johnson & Johnson COVID-19 Vaccine
Our Company
March 02, 2021
Johnson & Johnson Statement on Collaboration with Merck
Our Company
September 23, 2020
Johnson & Johnson Business Continuity Statement (9/23)
Our Company
August 13, 2020
Discussions Progress Between Johnson & Johnson and the European Commission Regarding Company’s Investigational COVID-19 Vaccine
Our Company
April 24, 2020
Statement of Support on Access to New COVID-19 Tools
Our Company
March 02, 2020
Johnson & Johnson Statement following White House Meeting on the Coronavirus
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue